3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Carcinoma, Hepatocellular
19
Carcinoma, Renal Cell
13
Parkinson Disease 4, Autosomal Dominant Lewy Body
10
Endometrial Neoplasms
6
Neoplasms
4
Biliary Tract Neoplasms
4
Neuroendocrine Tumors
3
Melanoma
3
Liver Neoplasms
3
Vulvar Neoplasms
2
Uterine Cervical Neoplasms
2
Triple Negative Breast Neoplasms
2
Stomach Neoplasms
2
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasm Metastasis
2
Colorectal Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Brain Neoplasms
2
von Hippel-Lindau Disease
1
Thyroid Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Skin Neoplasms
1
Penile Neoplasms
1
Multiple Endocrine Neoplasia Type 1
1
Lung Neoplasms
1
Kidney Neoplasms
1
Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer
1
Interventions
pembrolizumab
4
atezolizumab
3
Cetuximab
3
olaparib
2
Trastuzumab
2
Docetaxel
2
zimberelimab
1
tocilizumab
1
spartalizumab
1
ribociclib
1
pralsetinib
1
pertuzumab
1
pegylated granulocyte colony-stimulating factor
1
ipatasertib
1
inavolisib
1
fludarabine phosphate
1
fludarabine
1
entrectinib
1
encorafenib
1
cemiplimab
1
binimetinib
1
anlotinib
1
amivantamab
1
alectinib
1
adagrasib
1
Pemetrexed
1
Oxaliplatin
1
Nivolumab
1
Leucovorin
1
Irinotecan
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Solid Tumors
×
lenvatinib
×
90 days
×
Clear all
No trials found.